MarketCap
Facebook
X
Telegram
Verrica Pharmaceuticals Financial Ratios 2025-2011 | VRCA
Brief overview of Verrica Pharmaceuticals 's financial ratios
Current figures are compared with the company's own five-year history for 2021–2025.
Key multiples at the end of the period are P/S 1.87x (median 18.89x), P/B 2.7x (median 6.95x). On average, this basket is 75.7% below its own five-year medians. The market values the business at a discount to recent history.
Current measures of operating quality are ROE -72.3%, ROA -38%, ROCE -49.2%. Current return ratios are negative, materially weakening the fundamental profile.
Price, earnings and growth produce a PEG of 0.13x. A value below one indicates moderate pricing relative to expected growth.
The cash cycle lengthened by 587.3 days to 27.2 days. Operations require more funding.
Overall picture
Verrica Pharmaceuticals 's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Verrica Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3.7 | -0.4 | -3.7 | -10.3 | -6.5 | -6.9 | -12.9 | -8.5 | - | - | - | - | - | - | - |
P/S |
1.9 | 4.3 | 47.9 | 28.0 | 18.9 | - | - | - | - | - | - | - | - | - | - |
EPS |
-1.7 | -14.8 | -1.5 | -0.7 | -1.3 | -1.7 | -1.1 | -1.4 | -1.6 | - | - | - | - | - | - |
EV (Enterprise Value) |
58.9 M | 50.1 M | 238 M | 223 M | 258 M | 324 M | 357 M | 168 M | -8.05 M | 3.21 M | - | - | - | - | - |
EBITDA per Share |
-1.13 | -12.7 | -1.44 | -0.61 | -1.13 | -1.6 | -1.2 | -1.49 | - | - | - | - | - | - | - |
EV/EBITDA |
-4.9 | -0.8 | -3.6 | -10.7 | -8.1 | -8.8 | -11.9 | -7.6 | - | - | - | - | - | - | - |
PEG |
-0.02 | -0.0 | -0.25 | - | - | 0.13 | -0.65 | 0.06 | - | - | - | - | - | - | - |
P/B |
2.7 | -3.3 | 12.4 | 6.3 | 7.0 | 8.9 | 5.6 | 2.0 | - | - | - | - | - | - | - |
P/CF |
-3.8 | -0.5 | -6.4 | -13.5 | -8.2 | -9.3 | -12.9 | -9.4 | - | - | - | - | - | - | - |
ROE % |
-72.34 | 776.88 | -339.02 | -61.17 | -107.59 | -129.43 | -43.39 | -23.09 | - | - | - | - | - | - | - |
ROA % |
-37.98 | -141.50 | -82.11 | -54.76 | -43.78 | -57.57 | -41.22 | -22.47 | - | - | - | - | - | - | - |
ROCE % |
-49.25 | 668.55 | -332.74 | -53.20 | -94.80 | -115.87 | -46.23 | -24.46 | - | - | - | - | - | - | - |
Current Ratio |
2.1 | 0.8 | 1.3 | 9.5 | 1.7 | 1.7 | 19.4 | 36.8 | - | - | - | - | - | - | - |
DSO |
27.2 | 103.6 | 151.3 | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | 244.6 | 373.0 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | 306.0 | 1084.4 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
27.2 | 348.2 | 524.3 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
27.2 | 42.2 | -560.1 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Verrica Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.62 | -0.45 | -0.03 | 0.02 | -0.1 | - | -4.88 | -3.7 | -0.44 | - | -0.54 | -0.24 | -0.15 | - | - | -0.37 | -0.31 | - | -0.47 | -0.43 | -0.04 | - | -0.42 | -0.38 | -0.39 | -0.31 | -0.24 | -0.28 | -0.3 | -0.3 | -0.24 | -0.92 | -0.65 | -0.5 | -0.48 | -0.38 | -0.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.61 | -0.46 | 0.17 | 0.16 | -0.09 | - | -4.4 | -3.25 | -0.4 | - | - | -0.25 | -0.16 | - | 0.04 | -0.32 | -0.27 | - | -0.42 | -0.39 | - | - | -0.38 | -0.34 | -0.4 | -0.32 | -0.26 | -0.3 | -0.32 | -0.33 | -0.25 | -0.95 | -0.66 | -0.5 | -0.48 | -0.38 | -0.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-365.25 | -7.42 | 120.02 | 247.63 | -1099.41 | -1151.86 | -1210.49 | -1297.46 | -1436.84 | -88.63 | -88.44 | -92.07 | -105.55 | -95.39 | -126.80 | -149.56 | -88.82 | -55.49 | -87.28 | -84.40 | -91.60 | -90.09 | -101.84 | -79.41 | -61.66 | -43.39 | -40.11 | -37.35 | -32.53 | -23.09 | 5.77 | 31.67 | 53.17 | 20.38 | 19.30 | 15.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-61.63 | -48.21 | -56.29 | -86.28 | -112.33 | -89.24 | -89.24 | -106.90 | -83.46 | -52.80 | -52.63 | -43.13 | -37.29 | -27.69 | -42.14 | -54.20 | -39.04 | -27.21 | -41.35 | -39.59 | -40.94 | -40.07 | -51.24 | -46.00 | -43.54 | -41.22 | -38.31 | -35.83 | -31.39 | -22.47 | -30.02 | -38.56 | -44.83 | -15.80 | -14.96 | -12.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-382.78 | -34.93 | 86.38 | 210.26 | -1014.46 | -1058.22 | -1114.76 | -1196.53 | -1321.79 | -88.44 | -85.20 | -84.51 | -92.69 | -81.76 | -110.57 | -134.38 | -78.44 | -49.28 | -78.50 | -75.86 | -85.24 | -85.33 | -97.62 | -78.47 | -63.87 | -46.27 | -43.13 | -40.15 | -34.70 | -24.46 | 5.06 | 31.43 | 53.09 | 20.37 | 19.29 | 15.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.1 | 1.7 | 0.7 | 0.7 | 0.7 | 0.8 | - | 0.8 | 1.0 | 1.3 | 1.8 | 9.2 | 18.1 | 9.5 | 11.2 | 1.4 | 1.6 | 1.7 | 1.9 | 2.1 | 2.3 | 1.8 | 1.8 | 1.8 | 1.8 | 20.1 | 20.1 | 20.1 | 20.1 | 37.1 | 37.1 | 37.1 | 37.1 | 14.8 | 14.8 | 14.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
145.3 | 134.2 | 51.7 | 53.2 | 75.0 | - | -256.8 | 150.1 | 134.2 | - | 61.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | 320.8 | - | - | 339.1 | 229.5 | - | 42.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | 217.6 | - | - | 239.7 | 325.3 | - | 605.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 51.7 | 53.2 | 395.8 | - | - | 489.2 | 363.6 | - | 104.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 51.7 | 53.2 | 178.2 | - | - | 249.5 | 38.3 | - | -501.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Verrica Pharmaceuticals , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
